Navigation Links
Vince & Associates, Brad Vince Expands Early Phase Gastrointestinal Capabilities
Date:8/28/2013

Overland Park, KS (PRWEB) August 28, 2013

Vince & Associates Clinical Research, a premier provider of early phase clinical research services to the global biopharmaceutical industry, announced today the expansion of its capabilities in the gastrointestinal (GI) therapeutic area with the addition of a dedicated Endoscopy Suite at its Clinical Pharmacology Unit.

"Vince and Associates Clinical Research has successfully conducted a number of studies evaluating potential therapies in patients with gastrointestinal disorders. To supplement ongoing research, VACR has established an Endoscopy Suite to offer on-site access to a wide range of endoscopic procedures," said Dr. Brad Vince, CEO and medical director of Vince & Associates. "This investment reaffirms our dedication to providing research expertise in response to increasing demand for conducting clinical research in patient populations during early development, which often requires more specialized techniques."

The suite is equipped with advanced and minimally invasive video endoscopy technology from Olympus EndoTherapy. Procedures can be viewed remotely on a large screen and documented by video or still photography. The suite includes two sources of suction as well as resuscitation and medication stations to address patient safety and equipment is maintained at the purpose built disinfection station.

In addition to creating the Endoscopy Suite, VACR has reached out to Summit Gastroenterology for their medical expertise to complement the new research capabilities. Their Board Certified Gastroenterologists have been asked to join the Vince & Associates Clinical Research team as investigators, bringing significant clinical expertise as GI specialists.

Dr. Brad Vince stated, "The endoscopy suite and additional medical expertise significantly broaden the clinical research capabilities we are able to offer our clients. This investment will be key for clients seeking to obtain safety and efficacy data in patients and healthy normal volunteers during the early development phase to more quickly reach sound drug development decisions."

About Vince & Associates Clinical Research

Vince & Associates Clinical Research has provided clinical research services to the biopharmaceutical industry for more than a decade. Proud to be recognized in the industry as a "Center of Research Excellence", Vince & Associates has become a premier clinical research site by utilizing The Physician Research Model® of operation where study teams are led by highly experienced principal investigators intimately involved in all aspects of the clinical trial process.

Vince & Associates operates a state-of-the-art, multimillion-dollar, 90-bed clinical pharmacology unit that combines the ultimate in subject safety and luxury. This unit has the upscale atmosphere necessary for the recruitment and retention of study volunteers in both short- and long-term clinical trials, from the safety and security of the controlled access unit to the added features of a movie theater and game rooms.

About Altasciences

Altasciences is the parent company of wholly owned subsidiaries Vince & Associates Clinical Research (Kansas, USA) and Algorithme Pharma (Quebec, Canada). Both organizations provide comprehensive early stage clinical services in Phase I/IIa, including the necessary support services in this critical stage of drug development.

Read the full story at http://www.prweb.com/releases/brad-vince/research-expansion/prweb11067076.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dr. Bradley Vince of Vince & Associates in Kansas City Featured in Prominent Clinical Research Magazine
2. Clinical Immunology Society Appoints Vincent Bonagura, MD as Editor-in-Chief of the Journal of Clinical Immunology
3. American Federation for Aging Research Announces Recipients of Irving S. Wright and Vincent Cristofalo Scientific Awards
4. Preliminary Research, Led By Dr. Vincent Giampapa, Finds Aged Adult Stem Cells Can Be Functionally Reprogrammed To Act Like Younger Cells
5. St. Vincent, Austen BioInnovation Institute Announce Strategic Partnership to Develop New Products
6. China Green Agriculture Inc. Presented at Farmer Dailys Branded Fertilizer Roadshow in Shaanxi Province
7. HemoShear Hires Industry Business Development Veteran Vincent Aurentz as Chief Business Officer
8. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
11. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
Breaking Biology News(10 mins):